HIV medicine

Medical Journal of Australia

Volumn 176, Issue 1, 2002, Pages 21-

  Emery, Sean ^a   Cooper, David A ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; RNA DIRECTED DNA POLYMERASE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE TOXICITY; ANTIBIOTIC PROPHYLAXIS; BUDGET; CHRONIC TOXICITY; COST EFFECTIVENESS ANALYSIS; CROSS RESISTANCE; DEVELOPED COUNTRY; DRUG COST; DRUG EFFICACY; ENZYME INHIBITION; EPIDEMIC; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOTHERAPY; LIPODYSTROPHY; MORTALITY; PUBLIC HEALTH; QUALITY OF LIFE; SHORT SURVEY; SYMPTOM; VERTICAL TRANSMISSION; VIRUS REPLICATION;

EID: 0037033351     PISSN: 0025729X     EISSN: None     Source Type: Journal    
DOI: 10.5694/j.1326-5377.2002.tb04254.x     Document Type: Short Survey

References (5)

1. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatients Study Investigators
2. HIV disease progression in Australia in the time of combination antiretroviral therapies
3. Estimating the population impact in Australia of improved antiretroviral treatment for HIV infection
4. Expenditures for the case of HIV-infected patients in the era of highly active antiretroviral therapy
5. Diagnosis, prediction and natural course of HIV-1 protease inhibitor associated lipodystrophy, hyperlipidaemia and diabetes mellitus: A cohort study